secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628280-25-038981
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q2 2025 revenue $50M, net loss $60M; achieves $250M cost savings goal ahead of schedule
--------------------------------------------------------------------------------

- Total revenue $50M, down from $56M YoY; Cell Engineering rev up 8% to $39M; Biosecurity down to $10M.
- GAAP net loss $60M, improved from $217M YoY; Adjusted EBITDA -$28M, up from -$99M.
- Achieved $250M annualized cost reduction target three months ahead of schedule.
- Cash, equivalents, marketable securities $474M as of June 30, 2025.
- Reaffirmed FY2025 total revenue outlook $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828025038981/0001628280-25-038981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828025038981/dna-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer